Renovaro BioSciences to present cancer diagnostics research at ESMO Congress

RenovaroCube announces two scientific presentations at a leading cancer conference – the European Society for Medical Oncology, ESMO, Congress – on September 15, 2024. One presentation describes the development of a deep learning model that leverages cell-free DNA fragmentation features from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, the company was able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube’s current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes. A second study demonstrated the Cube platform’s ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood samples as an alternative for invasive tissue biopsies.